On June 18, 2020 KinaRx reported that it novel approach to treating lung and thyroid cancers is moving closer to clinical trials.

$399,933 SBIR Phase I grant from the National Cancer Institute to KinaRx, a Purdue University-affiliated startup, will help to advance a novel platform aimed at producing more effective drugs to treat lung and thyroid cancers. The platform targets gene mutations that help cancers grow and expand within the body.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Genetic and molecular characterization of cancer-driving kinase mutations has revolutionized the treatment of many types of cancer," said Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry.

KinaRx was founded by Sintim, who is its chief scientific officer, along with M. Javad Aman, Rena Lapidus, Ashkan Emadi, Frederick Holtsberg and Joe O’Neill.

The compounds under development by KinaRx were developed using Sintim’s platform, which rapidly makes complex drug molecules using bioinformatics, multi-component compound synthesis and the understanding of disease biology.

The team has focused on developing novel RET inhibitors, which are compounds designed to target the various cancer cells at work in the body. First-generation RET inhibitors demonstrated about 30% overall response rate (ORR) and no complete regression of tumors. New-generation RET inhibitors in clinical development only showed complete regression of RET-driven tumors in a small subset of patients (2-14%). These poor complete regression rates call for more efficacious RET inhibitors, which are active against drug-resistant mutant RET kinases.

"This Phase I SBIR grant will facilitate several preclinical experiments that are required to advance the novel RET inhibitors into clinical trials," said Sintim, who is a member of the Purdue University Center for Cancer Research and the Purdue Institute for Drug Discovery.

KinaRx has licensed drug compounds through the Purdue Research Foundation Office of Technology Commercialization, which is now located in the Convergence Center for Innovation and Collaboration in Discovery Park District, adjacent to the Purdue campus.

The researchers are looking for partners to continue testing and developing their technology. For more information on licensing and other opportunities, contact Sintim at [email protected].

On June 18, 2020 Bristol Myers Squibb reported a drug discovery collaboration with Ubiquigent that it inherited in its merger with Celgene (Press release, Bristol-Myers Squibb, JUN 18, 2020, View Source [SID1234561257]). The Big Pharma recently scrapped an alliance with Jounce Therapeutics that was formed by Celgene but is sticking with deubiquitinase (DUB) enzyme specialist Ubiquigent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celgene’s business was built around some of the areas in which Ubiquigent specializes. Thalidomide, Pomalyst and Revlimid—key drugs in Celgene’s product portfolio—all act on E3 ubiquitin ligases, a group of proteins involved in protein degradation. Celgene also struck protein degradation deals with Evotec, Nurix and Vividion Therapeutics in the years leading up to its merger with Bristol Myers.

In exploring the area, Celgene also entered into a drug discovery collaboration with Ubiquigent, a Scottish biotech that seeks to drive protein degradation through molecules that act on the ubiquitin system. Ubiquigent’s capabilities have landed it deals with companies including Forma Therapeutics.

SPONSORED BY CLINICAL INK
White Paper: Keep Your GI Trials Moving During COVID-19
Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.
DOWNLOAD NOW
Bristol Myers has less of a legacy in the field than Celgene does, but it appears to have decided to build on the experience it acquired in the takeover. Ubiquigent’s statement about the continuation of the deal it signed with Celgene follows comments by Bristol Myers about the potential to get at undruggable targets via the ubiquitin-proteasome system.

"We’ve realized we can degrade hundreds of previously unrecognized proteins, and this number is the tip of the iceberg. There is potentially the ability to target perhaps thousands of protein targets. We’ve just scratched the surface when it comes to understanding how many proteins we can target, and our job now is to figure out which have therapeutic utility," Bristol Myers Senior Vice President Mark Rolfe said in a statement.

Bristol Myers published the comments made by Rolfe, who joined the company in the Celgene deal, weeks before releasing a Q&A with Josh Hansen about protein homeostasis. Hansen, who like Rolfe worked at a West Coast site Bristol Myers acquired from Celgene, cited solid tumors and immune diseases as conditions potentially amenable to treatment through protein degradation.

On June 18, 2020 IVERIC bio, Inc. (Nasdaq: ISEE) (the "Company"), reported the pricing of an upsized underwritten public offering of 24,535,720 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,914,280 shares of its common stock at a price to the public of $4.099 per pre-funded warrant, in each case less underwriting discounts and commissions (Press release, Ophthotech, JUN 18, 2020, View Source [SID1234561248]). The purchase price of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. In addition, in connection with the public offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,967,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Concurrent with the public offering, the Company has agreed to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), 8,649,453 additional shares of its common stock to affiliates of Vivo Capital, LLC and Samsara BioCapital, LP, at a sale price equal to the price to the public in the public offering.

The aggregate gross proceeds from the public offering and the concurrent private placement are expected to be approximately $143.9 million, before underwriting discounts and commissions, placement agent fees and offering expenses payable by the Company, and without giving effect to any exercise by the underwriters of their option to purchase additional shares.

Cowen and Credit Suisse are acting as the book-running managers for the public offering and as placement agents for the concurrent private placement. Wedbush PacGrow is acting as lead manager for the public offering. The public offering and the concurrent private placement are expected to close on or about June 22, 2020, subject to customary closing conditions.

The public offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of an effective registration statement. A final prospectus supplement related to the public offering will be filed with the Securities and Exchange Commission (the "SEC") and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained, when available, by contacting: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by emailing [email protected], or by telephone: (833) 297-2926; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, or by telephone: (800) 221-1037, or by emailing [email protected].

The securities to be sold in the concurrent private placement have not been registered under the Securities Act, or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On June 18, 2020 CDDF reported that provides a neutral platform to stimulate interactions between all stakeholders involved in cancer drug development (Press release, EORTC, JUN 18, 2020, View Source [SID1234561242]). The aim of the organization is to accelerate the delivery of effective oncology agents to patients by encouraging multi-stakeholder discussions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will foster dialogue on common issues in clinical cancer research especially with other stakeholders. Both organisations intend to organise joint workshops and offer support and endorsement in each other’s events.

"Through the partnership with EORTC, one of the most important academic clinical research organizations worldwide, we believe we are offering unique value to stimulate advancement in oncology treatment and delivery" said Professor Jaap Verweij, CDDF Managing Director. "We believe collaboration is the key to improving outcomes for cancer patients and we look forward to a strong alliance with EORTC that will help identify and overcome challenges in the development and delivery of cancer drugs and deliver swift benefits to cancer patients."

"This is an important partnership for EORTC," said Dr Denis Lacombe, EORTC Director General. "CDDF has been instrumental in discussions with regulators and other stakeholders and with our combined efforts, we can bring challenging issues to the wider oncology community producing effective outcomes."

On June 18, 2020 ArcherDX, Inc. reported it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy (Press release, ArcherDX, JUN 18, 2020, View Source [SID1234561239]). PCM provides tumor-informed longitudinal analysis of circulating tumor DNA (ctDNA) found in patient blood where the quantity of ctDNA is a predictor of disease stage and burden, and achieves accuracy at low limits of detection by focusing the ctDNA analysis on known patient-specific mutations found in the tumor tissue.i ArcherDX and BMS will evaluate the clinical samples from cancer patient cohorts with the goal of advancing the use of MRD detection or ctDNA clearance to potentially inform future therapy selection and/or optimization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Collaborating with BMS, a leader in oncology, is a significant step toward accomplishing our common goal of improving patient outcomes. We are delighted BMS chose to leverage our Personalized Cancer Monitoring assays for clinical research aimed at expanding precision oncology into early-stage cancers, when the cancer is typically easier to cure compared to late-stage cancers," said Jason Myers, Chief Executive Officer and co-founder of ArcherDX. "This collaboration further underscores our intention to facilitate real-time monitoring of ctDNA during and after therapy with personalized, decentralized assays that can be distributed across the globe and could potentially optimize the use of current and future cancer therapies."

ArcherDX’s PCM development program is being advanced by ArcherDX and is supported by a collaboration led by Professor Charles Swanton of UCL and the Francis Crick Institute to detect evidence of disease progression in lung cancer patients from cell-free ctDNA as part of the Cancer Research UK-funded UCL-sponsored TRACERx study.[1] PCM applies ArcherDX’s proprietary Anchored Multiplex PCR (AMP) technology to accurately detect exceedingly low levels of cancer-derived DNA from patient blood.

About Personalized Cancer Monitoring
PCM is a patient-specific assay for monitoring residual disease, disease recurrence and progression of cancer. At initial diagnosis, exome sequencing of the surgically removed tumor or a tumor biopsy is used to identify patient-specific cancer mutations. A patient-specific assay is delivered to the laboratory affiliated with the patient’s care team. Clinicians use the personalized assay to measure ctDNA taken from non-invasive peripheral blood draws at specified intervals, producing a quantitative longitudinal view of the cancer’s evolution.

PCM is currently available and sold under a research use only (RUO) designation and is not yet approved for broad clinical use. Once it receives regulatory approval, PCM could ultimately expand the use of precision oncology to early-stage cancers, potentially providing faster diagnostic solutions in the future at local and regional laboratories inside and outside the U.S.